1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Homozygous Familial Hypercholesterolemia - Epidemiology Forecast to 2030

Homozygous Familial Hypercholesterolemia - Epidemiology Forecast to 2030

  • January 2021
  • 80 pages
  • ID: 6010466
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Homozygous familial hypercholesterolemia (HoFH) - Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Homozygous familial hypercholesterolemia (HoFH) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Homozygous Familial Hypercholesterolemia (HoFH) Understanding
Homozygous Familial Hypercholesterolemia (HoFH) is the more serious form of familial hypercholesterolemia (FH). FH is an autosomal dominant genetic disorder, meaning that only one parent needs to have the condition for his or her children to inherit it. HoFH is a rare and life-threatening disease originally characterized clinically by plasma cholesterol levels >13 mmol/L (>500 mg/dL), extensive xanthomas, and marked premature and progressive atherosclerotic cardiovascular disease (ACVD). It is defined as having two pathogenic mutations in two alleles of the causative genes. According to the National Institutes of Health, patients with HoFH have LDL cholesterol (LDL-C) levels three to six times higher than normal.
The physical signs of HoFH are generally more severe and occur at an earlier age than in patients with HeFH. Untreated patients with HoFH generally present with atherosclerosis, aortic valve disease, and coronary heart disease before the age of 20 years. The deposition of cholesterol in vascular and extravascular compartments, such as tendons and skin, results in xanthomas (yellow, waxy patches on your skin over the elbows, knees, and buttocks due to subcutaneous lipid depositions usually caused by derangement of lipoprotein metabolism) and the deposition of lipid in the cornea of the eyes causes corneal arcus and an increase in intraocular pressure. Some symptoms of heart disease include chest pain (angina), rapid heartbeat, and shortness of breath.
Most patients with genetically confirmed HoFH have two mutant alleles of the LDLR gene, and their parents have HeFH each. Mutations in alleles of three other genes were also identified as causal in some cases with a severe phenotype resembling HoFH. These secondary genes are ApoB encoding apolipoprotein (apo) B, PCSK9 encoding proprotein convertase subtilisin/kexin type 9 (PCSK9), and LDLRAP1 encoding LDL receptor adapter protein 1, which uniquely causes a recessive phenotype since carrier parents have normal lipid profiles. Patients are homozygotes, with the same mutation in both alleles of the same gene, or more commonly, compound heterozygotes with different mutations in each allele of the same gene, or double heterozygotes with mutations in two different genes affecting LDL receptor function. Irrespective of the underlying genetic defect, the severity of the HoFH phenotype depends on residual LDL receptor activity.

Homozygous Familial Hypercholesterolemia (HoFH) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Homozygous Familial Hypercholesterolemia (HoFH), Diagnosed Prevalence of Homozygous Familial Hypercholesterolemia (HoFH) and Mutation-specific Distribution of Homozygous Familial Hypercholesterolemia (HoFH) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Homozygous Familial Hypercholesterolemia (HoFH) Detailed Epidemiology Segmentation
• The prevalent population of HoFH in the seven major markets is estimated to be 3,882 in 2020.
• The diagnosed prevalent cases of HoFH, in the United States, is estimated to be 698 in 2020.
• HoFH can be divided into LDL Receptor (LDLR), Apolipoprotein B (Apo B), Proprotein Convertase Subtilin/Kexin 9 (PCSK9), and other rare mutations (SREBP2, and STAP1 genes, LDLRAP1 gene) based on the types of mutations causing the condition. In the United States, the number of cases of HoFH caused by LDLR, Apo B, PCSK9, and other rare mutations (SREBP2, and STAP1 genes, LDLRAP1 gene) was 587, 20, 13, and 33 respectively, in 2017.
• In the EU5 countries, the diagnosed prevalence of HoFH was maximum in Germany with 231 cases, followed by the France with 189 cases in 2017. While, the least number of cases were in Spain, with 131 cases in 2017.
• In Japan, the diagnosed prevalence of HoFH is estimated to be 215 in 2020.

Scope of the Report
• The report covers the descriptive overview of Homozygous Familial Hypercholesterolemia (HoFH), explaining its causes, signs and symptoms, pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Homozygous Familial Hypercholesterolemia (HoFH).
• The report provides the segmentation of the disease epidemiology for the 7MM by Prevalence of Homozygous Familial Hypercholesterolemia (HoFH), Diagnosed Prevalence of Homozygous Familial Hypercholesterolemia (HoFH) and Mutation-specific Distribution of Homozygous Familial Hypercholesterolemia (HoFH).

Report Highlights
• Eleven Years Forecast of Homozygous Familial Hypercholesterolemia (HoFH)
• 7MM Coverage
• The analyst has also analysed mutation-specific data of HoFH, which suggested that mutations in the LDLR gene is the most common causes of HoFH as compared to Apo B, PCSK9, and other rare mutations (SREBP2, and STAP1 genes, LDLRAP1 gene).

Key Questions Answered
• What is the disease risk, burden and unmet needs of Homozygous Familial Hypercholesterolemia (HoFH)?
• What is the historical Homozygous Familial Hypercholesterolemia (HoFH) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Homozygous Familial Hypercholesterolemia (HoFH) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Homozygous Familial Hypercholesterolemia (HoFH)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Homozygous Familial Hypercholesterolemia (HoFH) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The Homozygous Familial Hypercholesterolemia (HoFH) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Homozygous Familial Hypercholesterolemia (HoFH) market.
• Quantify patient share distribution in the 7MM for Homozygous Familial Hypercholesterolemia (HoFH).
• The Homozygous Familial Hypercholesterolemia (HoFH) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Homozygous Familial Hypercholesterolemia (HoFH) epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Congestive Heart Failure Treatment Device Market Research Report by Product, by End-User, by State - United States Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • October 2021
  • 196 pages

Congestive Heart Failure Treatment Device Market Research Report by Product (Cardiac Resynchronization Therapy, Implantable Cardioverter Defibrillator, and Pacemaker), by End-User (Ambulatory Surgery Cente ...

  • United States
  • Cardiac Management
  • Cardiovascular Disease
  • Industry analysis

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on